NASDAQ:KMPH - KemPharm Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.29 -0.01 (-0.43 %) (As of 02/19/2019 04:00 PM ET)Previous Close$2.30Today's Range$2.25 - $2.3852-Week Range$1.72 - $8.40Volume49,965 shsAverage Volume78,994 shsMarket Capitalization$60.58 millionP/E Ratio-0.77Dividend YieldN/ABeta1.85 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company has a collaboration agreement with twoXAR, Inc. to develop prodrug-based therapies for multiple therapeutic areas and indications. The company was founded in 2006 and is headquartered in Celebration, Florida. Receive KMPH News and Ratings via Email Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMPH Previous Symbol CUSIPN/A Webwww.kempharm.com Phone319-665-2575Debt Debt-to-Equity RatioN/A Current Ratio0.91 Quick Ratio0.91Price-To-Earnings Trailing P/E Ratio-0.77 Forward P/E Ratio-0.68 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.92) per share Price / Book-0.58Profitability EPS (Most Recent Fiscal Year)($2.96) Net Income$-43,380,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-141.00%Miscellaneous Employees32 Outstanding Shares26,455,000Market Cap$60.58 million OptionableOptionable KemPharm (NASDAQ:KMPH) Frequently Asked Questions What is KemPharm's stock symbol? KemPharm trades on the NASDAQ under the ticker symbol "KMPH." How were KemPharm's earnings last quarter? KemPharm Inc (NASDAQ:KMPH) released its quarterly earnings data on Friday, August, 10th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.31. View KemPharm's Earnings History. When is KemPharm's next earnings date? KemPharm is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for KemPharm. What price target have analysts set for KMPH? 6 analysts have issued 1 year target prices for KemPharm's stock. Their predictions range from $10.00 to $17.00. On average, they anticipate KemPharm's share price to reach $12.00 in the next year. This suggests a possible upside of 424.0% from the stock's current price. View Analyst Price Targets for KemPharm. What is the consensus analysts' recommendation for KemPharm? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KemPharm. What are Wall Street analysts saying about KemPharm stock? Here are some recent quotes from research analysts about KemPharm stock: 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (1/15/2019) 2. Canaccord Genuity analysts commented, "We are encouraged by KemPharm’s progress with the ADHD program, and believe it represents a significant value-creating opportunity in the coming quarters. We maintain our BUY rating and $11 PT on KMPH shares. Positive IV Human Abuse Potential data bode well for upcoming ADHD reads. KemPharm announced positive results for their KP415 human abuse study, showing drug liking scores similar to placebo when administered up to the highest safest dose. There was no significant difference in mean and placebo. However, there was a numerically significant difference in mean and d-methylphenidate at equimolar doses. Drug liking is a proxy for the potential for drug abuse." (5/10/2018) Has KemPharm been receiving favorable news coverage? News coverage about KMPH stock has trended somewhat positive on Tuesday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. KemPharm earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Who are some of KemPharm's key competitors? Some companies that are related to KemPharm include Savara (SVRA), Kamada (KMDA), Acer Therapeutics (ACER), MannKind (MNKD), Paratek Pharmaceuticals (PRTK), Syros Pharmaceuticals (SYRS), Synlogic (SYBX), LifeVantage (LFVN), resTORbio (TORC), Dova Pharmaceuticals (DOVA), Xeris Pharmaceuticals (XERS), Tocagen (TOCA), Strongbridge Biopharma (SBBP), Galectin Therapeutics (GALT) and Athersys (ATHX). Who are KemPharm's key executives? KemPharm's management team includes the folowing people: Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)Mr. Daniel L. Cohen, Exec. VP of Gov. & PR (Age 60)Dr. Sven Guenther, Exec. VP of R&D (Age 47)Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47) When did KemPharm IPO? (KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. Who are KemPharm's major shareholders? KemPharm's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Arete Wealth Advisors LLC (2.04%), Victory Capital Management Inc. (0.91%), Geode Capital Management LLC (0.65%), BlackRock Inc. (0.34%), Northern Trust Corp (0.16%) and Change Path LLC (0.14%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Institutional Ownership Trends for KemPharm. Which major investors are buying KemPharm stock? KMPH stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Victory Capital Management Inc., Change Path LLC, Arete Wealth Advisors LLC, Janney Montgomery Scott LLC, BlackRock Inc. and Northern Trust Corp. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View Insider Buying and Selling for KemPharm. How do I buy shares of KemPharm? Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is KemPharm's stock price today? One share of KMPH stock can currently be purchased for approximately $2.29. How big of a company is KemPharm? KemPharm has a market capitalization of $60.58 million. The specialty pharmaceutical company earns $-43,380,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. KemPharm employs 32 workers across the globe. What is KemPharm's official website? The official website for KemPharm is http://www.kempharm.com. How can I contact KemPharm? KemPharm's mailing address is 2500 CROSSPARK ROAD SUITE E126, CORALVILLE IA, 52241. The specialty pharmaceutical company can be reached via phone at 319-665-2575 or via email at [email protected] MarketBeat Community Rating for KemPharm (NASDAQ KMPH)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 268 (Vote Outperform)Underperform Votes: 166 (Vote Underperform)Total Votes: 434MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is the Current Ratio?